Your browser doesn't support javascript.
loading
Five-year annual incidence and clinico-molecular features of breast cancer after the last negative screening mammography at age 68-69.
Bucchi, Lauro; Ravaioli, Alessandra; Baldacchini, Flavia; Giuliani, Orietta; Mancini, Silvia; Vattiato, Rosa; Rossi, Paolo Giorgi; Campari, Cinzia; Canuti, Debora; Di Felice, Enza; de Bianchi, Priscilla Sassoli; Ferretti, Stefano; Bertozzi, Nicoletta; Falcini, Fabio.
Afiliação
  • Bucchi L; Romagna Cancer Registry, Romagna Cancer Institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"), Meldola, Forlì, Italy.
  • Ravaioli A; Romagna Cancer Registry, Romagna Cancer Institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"), Meldola, Forlì, Italy. alessandra.ravaioli@irst.emr.it.
  • Baldacchini F; Romagna Cancer Registry, Romagna Cancer Institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"), Meldola, Forlì, Italy.
  • Giuliani O; Romagna Cancer Registry, Romagna Cancer Institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"), Meldola, Forlì, Italy.
  • Mancini S; Romagna Cancer Registry, Romagna Cancer Institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"), Meldola, Forlì, Italy.
  • Vattiato R; Romagna Cancer Registry, Romagna Cancer Institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"), Meldola, Forlì, Italy.
  • Rossi PG; Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Campari C; Cancer Screening Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Canuti D; Department of Health, Regional Administration, Emilia-Romagna Region, Bologna, Italy.
  • Di Felice E; Department of Health, Regional Administration, Emilia-Romagna Region, Bologna, Italy.
  • de Bianchi PS; Department of Health, Regional Administration, Emilia-Romagna Region, Bologna, Italy.
  • Ferretti S; University of Ferrara and Local Health Authority, Ferrara, Italy.
  • Bertozzi N; Department of Health, Regional Administration, Emilia-Romagna Region, Bologna, Italy.
  • Falcini F; Romagna Cancer Registry, Romagna Cancer Institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"), Meldola, Forlì, Italy.
Eur Radiol ; 32(2): 834-841, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34363132
ABSTRACT

OBJECTIVE:

The European Commission Initiative on Breast Cancer recommendation for triennial screening of women aged 70-74 is based on very weak evidence. A cohort of Italian women who had their last biennial screening mammography at age 68-69 was followed up for 5 years, assumed to represent the interval to another hypothetical screening mammography, in order to determine the annual proportional incidence of interval breast cancer.

METHODS:

The cohort included 118,370 women. They had their last mammography between 1997 and 2008. Incident breast cancers were identified by record-linking the cohort with the regional breast cancer registry. The expected incidence in the age range 65-74 was estimated with an age-period-cohort model. The number of interval cancers was divided by the expected number to obtain their proportional incidence.

RESULTS:

Overall, there were 298,658 woman-years at risk with 371 interval cancers versus 988.8 expected. In the first, second, third, fourth, and fifth interval year, the proportional incidence was 0.09 (95% confidence interval, 0.06-0.13), 0.32 (0.25-0.39), 0.60 (0.49-0.73), 0.75 (0.60-0.92), and 0.81 (0.60-1.07), respectively. Between the second and the fifth year, tumour stage and molecular subtype did not change significantly.

CONCLUSION:

Though not supported by these findings, the proposal of triennial screening for women aged 70-74 merits further research, because the 95% confidence interval of the third-year proportional incidence of interval cancer included 0.50-the maximum limit considered acceptable for women aged 50-69. KEY POINTS • The third-year incidence of breast cancer relative to the expected one was 0.60 (95% confidence interval, 0.49-0.73). • Between the second and the fifth year, tumour stage and molecular subtype did not change significantly (p >0.10). • The proposal of a 3-year screening interval at age 70-74 merits further evaluation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mamografia Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mamografia Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article